As longevity science bridges the gap between laboratory concepts and clinical realities, researchers have demonstrated that the topical senolytic drug ABT-263 can dramatically reverse severe wound-healing impairments in older skin. The novel treatment specifically targets and eliminates toxic, damaged “senescent” cells that accumulate with age and stall tissue regeneration. By manipulating these cellular hallmarks of aging, the discovery provides a scalable roadmap for advanced wound care and regenerative dermatology in an aging global population.
About the Author
